Cargando…

Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody and toxin-drug combined together via a chemical linker. While the antibody and drug are of vital importance in the direct elimination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feld, Jonathan, Barta, Stefan K., Schinke, Carolina, Braunschweig, Ira, Zhou, Yiyu, Verma, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717303/ https://www.ncbi.nlm.nih.gov/pubmed/23651630

Ejemplares similares

An overview of antibody–drug conjugates in oncological practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020)

Signal transduction inhibitors in treatment of myelodysplastic syndromes
por: Bachegowda, Lohith, et al.
Publicado: (2013)

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
por: Theocharopoulos, Charalampos, et al.
Publicado: (2021)

Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation
por: Christie, R. James, et al.
Publicado: (2017)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Design and Validation of Linkers for Site-Specific Preparation of Antibody–Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site
por: Kumar, Amit, et al.
Publicado: (2020)

An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
por: Pal, Lal Bahadur, et al.
Publicado: (2023)

Antibody–Biopolymer Conjugates in Oncology: A Review
por: Chavda, Vivek P., et al.
Publicado: (2023)

Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)
por: Yao, Houzong, et al.
Publicado: (2016)

Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
por: Barok, Mark, et al.
Publicado: (2021)

Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
por: Costa, Maria José, et al.
Publicado: (2019)

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload
por: Kondrashov, Aleksei, et al.
Publicado: (2023)

Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates
por: Liu-Shin, Lily, et al.
Publicado: (2018)

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017)

Imaging mass spectrometry for the precise design of antibody-drug conjugates
por: Fujiwara, Yuki, et al.
Publicado: (2016)

Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
por: Wang, Yu-Jie, et al.
Publicado: (2017)

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
por: Liao, Michael Z., et al.
Publicado: (2021)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

A CD205-directed antibody drug conjugate – lymphoma precision oncology or sophisticated chemotherapy?
por: Rieke, Damian T., et al.
Publicado: (2020)

Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate
por: Qiu, Difei, et al.
Publicado: (2021)

Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency
por: Su, Dian, et al.
Publicado: (2021)

Ethynylphosphonamidates for the Rapid and Cysteine‐Selective Generation of Efficacious Antibody–Drug Conjugates
por: Kasper, Marc‐André, et al.
Publicado: (2019)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology
por: Weddell, Jared, et al.
Publicado: (2020)

Development of applicable thiol-linked antibody–drug conjugates with improved stability and therapeutic index
por: Wang, Yanming, et al.
Publicado: (2022)

Sulfatase-cleavable linkers for antibody-drug conjugates
por: Bargh, Jonathan D., et al.
Publicado: (2020)

Peroxide-cleavable linkers for antibody–drug conjugates
por: Ashman, Nicola, et al.
Publicado: (2023)

Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting
por: Evans, Reginald, et al.
Publicado: (2022)

A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
por: Vasalou, Christina, et al.
Publicado: (2015)

A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
por: Huang, Jing, et al.
Publicado: (2020)

Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates
por: Zhang, Donglu, et al.
Publicado: (2016)

Efficacy and Specificity of a Monoclonal Antibody‐Drug Conjugate in Chemotherapy by Intratumoral Injection
por: Kitamura, Kazuya, et al.
Publicado: (1992)

Divinylpyrimidine reagents generate antibody–drug conjugates with excellent in vivo efficacy and tolerability
por: Walsh, Stephen J., et al.
Publicado: (2022)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors
por: Anami, Yasuaki, et al.
Publicado: (2022)

Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review)
por: Sun, Te, et al.
Publicado: (2023)

Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates
por: Xu, Keyuan, et al.
Publicado: (2023)

Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer – The ABCs of ADCs (Antibody drug Conjugates)()
por: Martin, J., et al.
Publicado: (2023)

Investigating the Impact of Sample Preparation on Mass Spectrometry-Based Drug-To-Antibody Ratio Determination for Cysteine- and Lysine-Linked Antibody–Drug Conjugates
por: Källsten, Malin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vc2hodb1foelro1sla4jgp0ad7